Eli Lilly Posts Better-than-Expected Earnings for Q3 (Reuters)
Drug maker Eli Lilly and Co. reported better-than-expected third-quarter earnings today. The Indianapolis, Ind.-based Lilly earned $1.2 billion ($1.11 per share) in Q3, compared to $1.33 billion ($1.18 per share) in the previous year, beating analysts’ expectations slightly. Lilly’s shares closed the day at $50.15, up from the previous day’s close of $49.65. Earnings were powered by growth in the company’s drugs for depression, diabetes and cancer, in addition to cost-cutting measures. Lilly investors should expect to see similar returns in Q4.
Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:
Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.
Hilary Kramer is an investment analyst and portfolio manager with 30 years of experience on Wall Street. Since 2010, Hilary's financial publications have provided stock analysis and investment advice to her subscribers:
Jon Johnson's philosophy in investing and trading is to take what the market gives you regardless if that is to the upside or downside. For the past 21 years, Jon has helped thousands of clients gain success in the financial markets through his newsletters and education services: